CRISPR/Cas9 is a gene editing tool that has revolutionized biomedical research and led to the first FDA-approved CRISPR-based gene therapy. However, until now, the precise mechanism of exactly how ...

Researchers engineered and screened dozens of base editors to precisely target a single mutation without editing other portions of the DNA.

The 2020 Nobel Prize in Chemistry was awarded for the development of CRISPR/Cas9, a method also known as "gene scissors," which enables researchers to better understand how human cells function and ...

(Nanowerk News) The CRISPR-Cas gene scissors offer a wide range of potential applications, from the treatment of genetic diseases to antiviral therapies and diagnostics. However, to safely harness ...

In nature, the best-known CRISPR system, CRISPR-Cas9, cuts any RNA or DNA it recognizes as foreign, and thereby protects bacteria from viral attacks. Another CRISPR system, one that is relatively ...

CRISPR-Cas is an adaptive immune system of prokaryotes (bacteria and archaea). Apart from protecting its host against invading viruses, alternative biological functions of CRISPR-Cas have also been ...

The cryogenic electron microscope structure of the A4p-activated (green) CalpL protein filament (violet) from Candidatus Cloacimonas acidaminovorans (PDB ID: 9EYJ). CRISPR-Cas systems help to protect ...

Investigating small protein inhibitors of CRISPR–Cas — an adaptive immune system in bacteria — has led to the discovery of a mechanism for inhibiting a large macromolecular complex. AcrIF25, an ...

A research team led by scientists from the Helmholtz Institute for RNA-based Infection Research (HIRI) has introduced a new ...

A team of researchers led by Alan Davidson at the University of Toronto have discovered a small protein that can disassemble a stable bacterial CRISPR-Cas7 complex without using adenosine ...

Scientists captured high-resolution structures of the Tn7-like transpososome, a molecular machine that can cut and paste ...

CRISPR Therapeutics AG stock has surged nearly 90% since my Buy call in early May, reaching its highest value since February 2024. The rally builds on the historic approval of Casgevy, a gene editing ...